Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.
Panzuto F, Partelli S, Campana D, de Braud F, Spada F, Cives M, Tafuto S, Bertuzzi A, Gelsomino F, Bergamo F, Marcucci S, Mastrangelo L, Massironi S, Appetecchia M, Filice A, Badalamenti G, Bartolomei M, Amoroso V, Landoni L, Rodriquenz MG, Valente M, Colao A, Isidori A, Fanciulli G, Bollina R, Ciola M, Butturini G, Marconcini R, Arvat E, Cinieri S, Berardi R, Baldari S, Riccardi F, Spoto C, Giuffrida D, Gattuso D, Ferone D, Rinzivillo M, Bertani E, Versari A, Zerbi A, Lamberti G, Lauricella E, Pusceddu S, Fazio N, Dell'Unto E, Marini M, Falconi M. Panzuto F, et al. Among authors: de braud f. Endocrine. 2024 Apr;84(1):42-47. doi: 10.1007/s12020-023-03649-4. Epub 2024 Jan 4. Endocrine. 2024. PMID: 38175391 Free PMC article. Review.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study.
Brunelli C, Borreani C, Caraceni A, Roli A, Bellazzi M, Lombi L, Zito E, Pellegrini C, Spada P, Kaasa S, Foschi AM, Apolone G; PATIENT VOICES study group. Brunelli C, et al. Health Qual Life Outcomes. 2020 Jul 28;18(1):252. doi: 10.1186/s12955-020-01501-1. Health Qual Life Outcomes. 2020. PMID: 32723341 Free PMC article.
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A. Urtecho SB, et al. Among authors: de braud fgm. Lung Cancer. 2024 Dec 9;199:108051. doi: 10.1016/j.lungcan.2024.108051. Online ahead of print. Lung Cancer. 2024. PMID: 39740426
Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, Zanenga L, Depretto C, Folli S, Scaperrotta G, Capri G, Bianchi GV, Ferraris C, Martelli G, Maugeri I, Provenzano L, Nichetti F, Agnelli L, Lobefaro R, Fucà G, Fotia G, Mariani L, Morelli D, Ladisa V, De Santis MC, Lozza L, Trecate G, Belfiore A, Brich S, Bertolotti A, Lorenzini D, Ficchì A, Martinetti A, Sottotetti E, Arata A, Corsetto P, Sorrentino L, Rediti M, Salvadori G, Minucci S, Foiani M, Apolone G, Pagani M, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: de braud f. Cell Metab. 2024 Dec 17:S1550-4131(24)00450-9. doi: 10.1016/j.cmet.2024.11.004. Online ahead of print. Cell Metab. 2024. PMID: 39694040
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, Lombardi P, Daniele G, Botticelli A, Lo Russo G, De Braud F, Marchetti P, Nuti M, Ferretti E, Farina L, Rughetti A, Petti M. Filetti M, et al. Among authors: de braud f. Cancers (Basel). 2024 Nov 26;16(23):3955. doi: 10.3390/cancers16233955. Cancers (Basel). 2024. PMID: 39682144 Free PMC article.
Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, Ambrosini P, Fotia G, Hüllein J, Randon G, Lajer P, Perrone F, Tamborini E, Leoncini G, Coppa J, Busset MDD, Pusceddu S, Milione M, Morano F, Pietrantonio F, Pruneri G, Mazzaferro V, Lipka DB, Köhler BC, Hübschmann D, Fröhling S, de Braud F, Niger M. Nichetti F, et al. Among authors: de braud f. Cancer Med. 2024 Dec;13(23):e70393. doi: 10.1002/cam4.70393. Cancer Med. 2024. PMID: 39618336 Free PMC article.
687 results